Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus.
Macaluso FS, Caprioli F, Benedan L, Bezzio C, Caporali R, Cauli A, Chimenti MS, Ciccia F, D'Angelo S, Fantini MC, Festa S, Iannone F, Lubrano E, Mariani P, Papi C, Provenzano G, Pugliese D, Rispo A, Saibeni S, Salvarani C, Variola A, Zenga M, Armuzzi A, Orlando A, Gerli R. Macaluso FS, et al. Among authors: fantini mc. Autoimmun Rev. 2024 May;23(5):103533. doi: 10.1016/j.autrev.2024.103533. Epub 2024 Mar 22. Autoimmun Rev. 2024. PMID: 38521214 Free article. Review.
Corrigendum to "Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease" [Dig. Liver Dis. 48 (2016) 360-370].
Armuzzi A, Gionchetti P, Daperno M, Danese S, Orlando A, Scribano ML, Vecchi M, Rizzello F; GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group. Armuzzi A, et al. Dig Liver Dis. 2016 Sep;48(9):1103. doi: 10.1016/j.dld.2016.06.015. Dig Liver Dis. 2016. PMID: 27555348 No abstract available.
Pragmatic trial design to compare real-world effectiveness of different treatments for inflammatory bowel diseases: the PRACTICE-IBD European consensus.
Fantini MC, Fiorino G, Colli A, Laharie D, Armuzzi A, Caprioli FA, Gisbert JP, Kirchgesner J, Macaluso FS, Magro F, Ghosh S; PRACTICE-IBD study group. Fantini MC, et al. J Crohns Colitis. 2024 Feb 17:jjae026. doi: 10.1093/ecco-jcc/jjae026. Online ahead of print. J Crohns Colitis. 2024. PMID: 38367197 Free article.
Development of Ac2-26 Mesoporous Microparticle System as a Potential Therapeutic Agent for Inflammatory Bowel Diseases.
Broering MF, Oseliero Filho PL, Borges PP, da Silva LCC, Knirsch MC, Xavier LF, Scharf P, Sandri S, Stephano MA, de Oliveira FA, Sayed IM, Gamarra LF, Das S, Fantini MCA, Farsky SHP. Broering MF, et al. Among authors: fantini mca. Int J Nanomedicine. 2024 Apr 12;19:3537-3554. doi: 10.2147/IJN.S451589. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38638365 Free PMC article.
Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey.
Vernero M, Bezzio C, Ribaldone DG, Caprioli FA, Fantini MC, Festa S, Macaluso FS, Orlando A, Pugliese D, Renna S, Rispo A, Savarino EV, Variola A, Saibeni S; Italian Group for Inflammatory Bowel Disease (IG-IBD). Vernero M, et al. Among authors: fantini mc. J Clin Med. 2024 Mar 23;13(7):1857. doi: 10.3390/jcm13071857. J Clin Med. 2024. PMID: 38610623 Free PMC article.
Ordered mesoporous silicas for potential applications in solid vaccine formulations.
Miranda MCR, Nunes CM, Santos LF, da Silva LB, de Jesus VR, Filho NA, Pedro JAF, Lopes JLS, Oliveira CLP, Fantini MCA, Cardoso JS, Trezena AG, Ribeiro OG, Sant'Anna OA, Tino-De-Franco M, Martins TS. Miranda MCR, et al. Among authors: fantini mca. Vaccine. 2024 Jan 25;42(3):689-700. doi: 10.1016/j.vaccine.2023.12.032. Epub 2023 Dec 24. Vaccine. 2024. PMID: 38145911
132 results